Global Smart Biopsy Devices Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Smart Biopsy Devices Market Size

• The global smart biopsy devices market size was valued at USD 3.04 billion in 2025 and is expected to reach USD 4.88 billion by 2033, at a CAGR of 6.12% during the forecast period
• The market growth is largely fueled by the increasing adoption of advanced diagnostic technologies and the growing demand for early and accurate cancer detection, leading to greater utilization of smart biopsy devices across hospitals, diagnostic centers, and oncology clinics
• Furthermore, rising investments in precision medicine, increasing prevalence of cancer, and the growing integration of imaging-guided and minimally invasive biopsy technologies are establishing smart biopsy devices as essential tools in modern diagnostic procedures. These converging factors are accelerating the uptake of Smart Biopsy Devices solutions, thereby significantly boosting the industry's growth

Smart Biopsy Devices Market Analysis

• Smart biopsy devices, integrating advanced imaging, sensor-based guidance, and minimally invasive technologies, are increasingly vital components of modern cancer diagnostics across hospitals, specialty clinics, and diagnostic centers due to their ability to improve biopsy accuracy, reduce procedural complications, and enhance early disease detection
• The escalating demand for smart biopsy devices is primarily fueled by the rising global prevalence of cancer, growing adoption of image-guided biopsy procedures, and increasing demand for minimally invasive diagnostic techniques that enable precise tissue sampling and faster clinical decision-making
• North America dominated the smart biopsy devices market with the largest revenue share of approximately 41.9% in 2025, supported by advanced healthcare infrastructure, strong adoption of innovative diagnostic technologies, and the presence of leading medical device manufacturers. The U.S. is experiencing substantial growth in smart biopsy device adoption across hospitals, oncology centers, and diagnostic laboratories due to increasing cancer screening programs and the rising demand for precision diagnostics
• Asia-Pacific is expected to be the fastest-growing region in the smart biopsy devices market during the forecast period, registering a CAGR of approximately 9.5%, driven by expanding healthcare infrastructure, increasing cancer prevalence, and rising investments in advanced diagnostic technologies across countries such as China, Japan, and India
• The Needle-Based Biopsy Instruments segment dominated the largest market revenue share of around 46.8% in 2025, driven by their widespread use in diagnostic procedures for various cancers and tissue abnormalities

Report Scope and Smart Biopsy Devices Market Segmentation        

Smart Biopsy Devices Market Trends

“Increasing Integration of Advanced Imaging and Precision Technologies”

• A significant and accelerating trend in the global smart biopsy devices market is the growing integration of advanced imaging technologies and precision-guided systems to enhance biopsy accuracy and diagnostic efficiency. These technologies allow clinicians to perform minimally invasive tissue sampling with improved targeting of suspicious lesions, particularly in oncology diagnostics
• For instance, the Smart Biopsy System developed by BiBBInstruments AB is designed to improve tissue sampling in endoscopic ultrasound-guided biopsies, enabling physicians to collect high-quality core tissue samples for more accurate histological diagnosis
• Smart biopsy devices increasingly incorporate imaging modalities such as ultrasound guidance, MRI-guided navigation, and real-time digital imaging to precisely identify abnormal tissues. These technologies help clinicians target tumors or lesions with greater precision while minimizing damage to surrounding healthy tissue, improving patient outcomes and diagnostic reliability
• In addition, manufacturers are integrating digital connectivity and automated features into biopsy systems, allowing clinicians to capture procedural data, improve workflow efficiency, and enhance diagnostic documentation. These systems support improved coordination between radiologists, pathologists, and oncologists involved in cancer diagnosis
• The rising demand for minimally invasive diagnostic procedures, particularly for cancer detection, is encouraging healthcare providers to adopt technologically advanced biopsy devices capable of delivering rapid and accurate tissue sampling. As cancer screening programs expand globally, hospitals and diagnostic centers are increasingly investing in smart biopsy technologies
• Consequently, companies such as Hologic, Inc. and BD (Becton, Dickinson and Company) are focusing on developing advanced biopsy solutions with enhanced imaging compatibility, ergonomic designs, and improved sampling mechanisms to support precision diagnostics

Smart Biopsy Devices Market Dynamics

Driver

“Rising Prevalence of Cancer and Increasing Demand for Early Diagnosis”

• The increasing global burden of cancer, coupled with the growing emphasis on early detection and accurate diagnosis, is a significant driver for the adoption of smart biopsy devices across hospitals, diagnostic laboratories, and specialized oncology centers
• For instance, the introduction of the Brevera breast biopsy system by Hologic, Inc. has improved breast cancer diagnostics by enabling real-time tissue verification and streamlined biopsy workflows, helping clinicians achieve faster and more reliable diagnostic outcomes
• Smart biopsy devices play a critical role in oncology diagnostics by enabling minimally invasive tissue sampling from suspicious tumors in organs such as the breast, prostate, lung, and liver. These procedures allow physicians to confirm malignancies quickly and initiate appropriate treatment strategies for patients
• Increasing government initiatives and cancer screening programs across developed and emerging economies are further driving demand for biopsy procedures. Early detection campaigns and expanding diagnostic infrastructure are encouraging healthcare providers to adopt technologically advanced biopsy devices
• Furthermore, advancements in imaging technologies such as ultrasound-guided and MRI-guided biopsy procedures are improving diagnostic precision, enabling clinicians to identify smaller lesions and obtain accurate tissue samples with minimal complications
• The expansion of healthcare infrastructure, rising healthcare expenditure, and increasing investments in oncology research are collectively supporting the adoption of smart biopsy devices across hospitals, ambulatory surgical centers, and specialized diagnostic facilities

Restraint/Challenge

“High Procedural Costs and Technical Complexity of Advanced Biopsy Systems”

• The high cost associated with advanced biopsy devices and imaging-guided biopsy procedures remains a key challenge for market expansion, particularly in developing and resource-limited healthcare systems. These technologies often require specialized equipment and trained medical professionals, increasing the overall cost of diagnosis
• For instance, MRI-guided biopsy procedures utilizing advanced biopsy systems from companies such as Siemens Healthineers can involve high operational and equipment costs, limiting accessibility in smaller healthcare facilities and developing regions
• In addition, the operation of sophisticated biopsy systems often requires highly skilled clinicians and specialized training, which may not be readily available in all healthcare institutions. This can restrict the widespread adoption of smart biopsy technologies, particularly in rural or underdeveloped healthcare settings
• Procedural risks such as bleeding, infection, or sampling errors can also pose challenges, requiring continuous technological improvements and training to ensure safe and effective biopsy procedure
• Regulatory approval processes for advanced medical devices can be complex and time-consuming, as manufacturers must demonstrate safety, accuracy, and clinical effectiveness before commercialization. These regulatory hurdles can delay product launches and limit market entry for new companies
• Furthermore, limited reimbursement policies for certain biopsy procedures in some healthcare systems may discourage healthcare providers from adopting advanced biopsy technologies, slowing market penetration in price-sensitive markets

Smart Biopsy Devices Market Scope

The Smart Biopsy Devices market is segmented on the basis of application, product, guidance technique, and end user.

• By Application

On the basis of application, the Smart Biopsy Devices market is segmented into Breast Cancer, Skin Cancer, Liver Cancer, Prostate Cancer, and Others. The Breast Cancer segment dominated the largest market revenue share of approximately 41.6% in 2025, driven by the high global prevalence of breast cancer and increasing screening programs for early detection. Smart biopsy devices are widely used for breast tissue sampling due to their precision, minimally invasive nature, and ability to provide accurate diagnostic results. Hospitals and diagnostic centers increasingly rely on advanced biopsy technologies such as image-guided and vacuum-assisted devices to improve patient outcomes. The segment benefits from strong awareness initiatives, government screening campaigns, and expanding mammography programs worldwide. Technological advancements in biopsy needles and imaging guidance systems have improved diagnostic accuracy and reduced patient discomfort. Increasing demand for early-stage cancer detection and personalized treatment planning further supports segment growth. Rising healthcare investments and improvements in diagnostic infrastructure, particularly in emerging economies, are also contributing to higher adoption. In addition, growing collaborations between medical device manufacturers and healthcare providers ensure the availability of innovative biopsy systems. North America and Europe dominate this segment due to well-established cancer screening infrastructure and advanced healthcare systems. Overall, the breast cancer segment continues to lead due to its high diagnostic demand and widespread clinical adoption of biopsy procedures.

The Prostate Cancer segment is expected to witness the fastest CAGR of 11.7% from 2026 to 2033, fueled by the rising incidence of prostate cancer among aging male populations globally. Smart biopsy devices enable accurate tissue sampling and improved detection of clinically significant tumors, particularly through image-guided techniques such as MRI-guided biopsies. Increasing awareness regarding early prostate cancer diagnosis and screening programs is encouraging patients to undergo biopsy procedures. Technological innovations in biopsy devices, including robotic-assisted and targeted biopsy systems, are significantly improving diagnostic precision and reducing procedural complications. Hospitals and urology clinics are increasingly integrating advanced biopsy technologies to enhance diagnostic capabilities. The segment also benefits from growing adoption of multiparametric MRI combined with targeted biopsy approaches for improved cancer detection rates. Rising healthcare expenditure and the expansion of specialized oncology and urology centers further support segment growth. Emerging economies are witnessing increased adoption due to improving healthcare infrastructure and growing cancer awareness. In addition, ongoing clinical research and technological innovation in prostate biopsy devices continue to drive market expansion.

• By Product

On the basis of product, the Smart Biopsy Devices market is segmented into Needle-Based Biopsy Instruments, Procedure Trays, Localization Wires, and Other Products. The Needle-Based Biopsy Instruments segment dominated the largest market revenue share of around 46.8% in 2025, driven by their widespread use in diagnostic procedures for various cancers and tissue abnormalities. These instruments allow physicians to obtain precise tissue samples with minimal invasiveness, making them essential tools in modern oncology diagnostics. Hospitals and diagnostic centers rely heavily on core biopsy needles, fine-needle aspiration devices, and vacuum-assisted biopsy systems for accurate diagnosis. Technological advancements have improved needle precision, sample quality, and patient safety, increasing the reliability of biopsy procedures. The growing prevalence of cancer and the rising number of diagnostic procedures globally further support demand for needle-based biopsy devices. In addition, these instruments are compatible with multiple imaging guidance techniques, enhancing their clinical versatility. Increased physician preference for minimally invasive diagnostic tools also contributes to the segment’s dominance. Regulatory approvals and the development of advanced smart biopsy systems further strengthen market penetration. Furthermore, the integration of biopsy needles with digital imaging technologies improves diagnostic efficiency and patient outcomes.

The Localization Wires segment is expected to witness the fastest CAGR of 10.9% from 2026 to 2033, driven by their increasing use in preoperative localization of non-palpable tumors, particularly in breast cancer surgeries. Localization wires help surgeons accurately identify abnormal tissue areas before surgical removal, ensuring more precise tumor excision. Growing adoption of image-guided localization procedures in hospitals and cancer treatment centers is accelerating segment growth. Technological advancements in wire design, flexibility, and imaging compatibility have enhanced procedural efficiency and patient safety. Rising demand for minimally invasive and targeted surgical procedures further supports adoption. Increasing breast cancer screening programs and early detection initiatives globally are also boosting the demand for localization wires. In addition, hospitals prefer these devices due to their cost-effectiveness and ease of use during surgical planning. Expansion of specialized oncology centers and improvements in imaging technologies further drive the segment. Emerging economies are witnessing higher demand as diagnostic infrastructure continues to improve.

• By Guidance Technique

On the basis of guidance technique, the Smart Biopsy Devices market is segmented into Ultrasound-Guided Biopsy, Stereotactic-Guided Biopsy, Magnetic Resonance Imaging (MRI)-Guided Biopsy, and Other Guidance Techniques. The Ultrasound-Guided Biopsy segment dominated the largest market revenue share of approximately 44.3% in 2025, driven by its widespread availability, real-time imaging capability, and cost-effectiveness. Ultrasound-guided procedures allow clinicians to visualize tissues during the biopsy process, improving accuracy and reducing complications. Hospitals and diagnostic centers frequently use this technique for breast, liver, and thyroid biopsies due to its non-invasive nature and rapid results. The segment benefits from increasing cancer diagnosis rates and growing demand for minimally invasive diagnostic procedures. Technological advancements in ultrasound imaging systems have improved resolution and diagnostic accuracy. The portability and affordability of ultrasound equipment also encourage adoption in smaller clinics and emerging markets. In addition, clinicians prefer ultrasound-guided biopsy for its ability to provide immediate visualization of needle placement. Increasing investments in diagnostic imaging infrastructure further support segment growth.

The MRI-Guided Biopsy segment is expected to witness the fastest CAGR of 12.2% from 2026 to 2033, driven by its superior imaging capabilities and ability to detect lesions that may not be visible through other imaging techniques. MRI-guided biopsies are particularly useful in diagnosing complex cancers such as prostate and breast cancer. The technology offers high-resolution imaging and precise lesion targeting, improving diagnostic accuracy and reducing false-negative results. Hospitals and advanced diagnostic centers increasingly adopt MRI-guided systems for complex biopsy procedures. Growing adoption of precision medicine and personalized cancer diagnostics further supports this segment. Technological innovations in MRI-compatible biopsy devices and robotic-assisted systems enhance procedural efficiency. Increasing investment in advanced imaging infrastructure and research in oncology diagnostics also contribute to segment growth. The rising prevalence of cancer and growing demand for early detection further accelerate adoption.

• By End User

On the basis of end user, the Smart Biopsy Devices market is segmented into Hospitals, Academic and Research Institutes, and Diagnostic and Imaging Centers. The Hospitals segment dominated the largest market revenue share of approximately 52.7% in 2025, due to the high volume of biopsy procedures performed in hospital settings. Hospitals possess advanced diagnostic infrastructure, skilled healthcare professionals, and specialized oncology departments that support the widespread use of smart biopsy devices. The segment benefits from increasing hospital admissions related to cancer diagnosis and treatment. In addition, hospitals are early adopters of advanced medical technologies, including image-guided biopsy systems. The availability of multidisciplinary medical teams ensures accurate diagnosis and effective patient management. Rising healthcare investments and expanding hospital infrastructure globally further support market growth. Hospitals also participate in clinical trials and research initiatives involving advanced biopsy technologies. Furthermore, the integration of digital imaging systems and smart diagnostic platforms enhances biopsy procedure efficiency and accuracy.

The Diagnostic and Imaging Centers segment is expected to witness the fastest CAGR of 11.4% from 2026 to 2033, driven by the growing demand for specialized diagnostic services and outpatient procedures. These centers focus on imaging-based diagnostic solutions and often offer advanced biopsy procedures with shorter waiting times. Increasing preference for cost-effective and efficient diagnostic services is encouraging patients to visit specialized centers rather than large hospitals. The segment also benefits from the rising number of independent imaging facilities and diagnostic laboratories worldwide. Technological advancements in imaging modalities and biopsy guidance systems further enhance diagnostic capabilities. In addition, the expansion of private healthcare services and diagnostic networks in emerging markets supports segment growth. Growing awareness of early cancer detection and the increasing availability of advanced imaging technologies are expected to accelerate the adoption of smart biopsy devices in diagnostic centers globally.

Smart Biopsy Devices Market Regional Analysis

• North America dominated the smart biopsy devices market with the largest revenue share of approximately 41.9% in 2025, supported by advanced healthcare infrastructure, strong adoption of innovative diagnostic technologies, and the presence of leading medical device manufacturers. The region benefits from well-established hospital networks, specialized oncology centers, and extensive diagnostic laboratory infrastructure that actively utilize advanced biopsy technologies for accurate cancer detection and tissue analysis
• For instance, healthcare providers across the U.S. and Canada are increasingly adopting advanced biopsy technologies developed by companies such as Hologic, Inc. and BD (Becton, Dickinson and Company), which offer image-guided biopsy systems designed to improve diagnostic accuracy and workflow efficiency in breast and prostate cancer diagnostics
• The market is experiencing substantial growth in smart biopsy device adoption across hospitals, oncology centers, and diagnostic laboratories due to increasing cancer screening programs and the rising demand for precision diagnostics. Government initiatives promoting early cancer detection, combined with strong healthcare spending and ongoing technological advancements in minimally invasive diagnostic procedures, are further strengthening market expansion across North America

U.S. Smart Biopsy Devices Market Insight

The U.S. smart biopsy devices market captured the largest revenue share within North America in 2025, driven by the presence of advanced healthcare infrastructure, increasing cancer prevalence, and strong investments in diagnostic innovation. Hospitals and specialized cancer centers are increasingly utilizing technologically advanced biopsy devices to improve the accuracy and efficiency of tissue sampling procedures. The growing focus on early cancer detection programs, along with the rising adoption of image-guided biopsy procedures such as ultrasound-guided and MRI-guided biopsies, is significantly contributing to market growth. In addition, collaborations between medical device manufacturers and healthcare institutions for the development of next-generation biopsy technologies continue to accelerate innovation in the U.S. market.

Europe Smart Biopsy Devices Market Insight

The Europe smart biopsy devices market is projected to expand at a substantial CAGR throughout the forecast period, driven by rising cancer incidence, strong healthcare systems, and increasing investments in advanced diagnostic technologies. Countries such as Germany, France, and the U.K. are actively promoting early cancer screening programs and precision medicine initiatives, which are encouraging the adoption of technologically advanced biopsy solutions. The region also benefits from strong regulatory frameworks and government-funded healthcare systems that support the integration of innovative medical devices into clinical practice.

U.K. Smart Biopsy Devices Market Insight

The U.K. smart biopsy devices market is anticipated to grow at a noteworthy CAGR during the forecast period, supported by expanding cancer screening initiatives and strong investments in healthcare modernization. The country’s National Health Service (NHS) has been actively promoting early detection programs for cancers such as breast, prostate, and lung cancer, increasing the demand for reliable biopsy technologies. Furthermore, growing adoption of minimally invasive diagnostic procedures and increasing research collaborations between universities and medical device companies are supporting market development in the U.K.

Germany Smart Biopsy Devices Market Insight

The Germany smart biopsy devices market is expected to expand at a considerable CAGR during the forecast period, supported by the country’s well-developed healthcare infrastructure and strong medical technology industry. Germany hosts numerous specialized diagnostic laboratories and research institutions focused on oncology and molecular diagnostics, driving the adoption of advanced biopsy systems. Increasing investments in precision medicine and diagnostic innovation, along with strong government support for healthcare research, are further contributing to the growth of smart biopsy technologies across the country.

Asia-Pacific Smart Biopsy Devices Market Insight

The Asia-Pacific smart biopsy devices market is expected to be the fastest-growing region during the forecast period, registering a CAGR of approximately 9.5%. Growth in the region is driven by expanding healthcare infrastructure, increasing cancer prevalence, and rising investments in advanced diagnostic technologies across countries such as China, Japan, and India. Governments across the region are strengthening healthcare systems and promoting early cancer detection programs, which is significantly increasing demand for advanced biopsy devices in hospitals and diagnostic centers.

Japan Smart Biopsy Devices Market Insight

The Japan smart biopsy devices market is gaining momentum due to the country’s advanced healthcare system, strong focus on medical innovation, and increasing demand for early cancer diagnosis. Hospitals and research institutions are actively adopting technologically advanced diagnostic equipment to improve cancer detection rates and patient outcomes. In addition, Japan’s aging population and increasing incidence of chronic diseases are encouraging healthcare providers to adopt efficient and minimally invasive biopsy procedures.

China Smart Biopsy Devices Market Insight

The China smart biopsy devices market accounted for the largest market revenue share in Asia Pacific in 2025, attributed to the country’s rapidly expanding healthcare infrastructure, growing cancer burden, and strong government support for advanced medical technologies. China has significantly increased investments in hospital modernization and diagnostic laboratories, enabling greater adoption of advanced biopsy systems. In addition, the presence of domestic medical device manufacturers and increasing collaborations with international companies are helping accelerate the availability and adoption of smart biopsy technologies across the country.

Smart Biopsy Devices Market Share

The Smart Biopsy Devices industry is primarily led by well-established companies, including:

• Hologic, Inc. (U.S.)
• BD (U.S.)
• Danaher Corporation (U.S.)
• Medtronic (Ireland)
• Cook Medical (U.S.)
• B. Braun S.E. (Germany)
• Boston Scientific Corporation (U.S.)
• Argon Medical Devices, Inc. (U.S.)
• Devicor Medical Products, Inc. (U.S.)
• INRAD, Inc. (U.S.)
• Fujifilm Holdings Corporation (Japan)
• Stryker Corporation (U.S.)
• Cardinal Health, Inc. (U.S.)
• Koninklijke Philips N.V. (Netherlands)
• Siemens Healthineers AG (Germany)
• Olympus Corporation (Japan)
• Terumo Corporation (Japan)
• Planmed Oy (Finland)
• Merit Medical Systems, Inc. (U.S.)
• Abbott Laboratories (U.S.)

Latest Developments in Global Smart Biopsy Devices Market

• In August 2022, Mammotome announced the launch of the Mammotome DualCore Dual Stage Core Biopsy System, an advanced biopsy device designed to improve tissue sampling accuracy and procedural efficiency. The system features programmable firing modes and ergonomic one-handed operation, enabling clinicians to access difficult lesions while minimizing needle movement and vibration, thereby improving patient comfort and diagnostic accuracy
• In September 2024, Sensome announced the enrollment of the first patients in a first-in-human study evaluating a real-time tumor confirmation technology integrated into biopsy needles. The technology uses miniaturized impedance-based sensors and predictive algorithms to identify cancerous tissue in situ during biopsy procedures, enabling clinicians to confirm accurate sampling during the procedure itself
• In March 2025, LEADOPTIK and Stanford Medicine announced a research collaboration to develop AI-enhanced real-time optical imaging technology for lung biopsy procedures. The partnership focuses on integrating intelligent imaging capabilities into biopsy tools to help physicians better assess lesions during procedures and improve diagnostic accuracy in lung cancer detection
• In April 2025, Koelis announced a partnership with Bot Image to combine its Trinity MRI-fusion biopsy guidance system with the ProstatID AI-based lesion detection platform. The integration aims to enhance prostate cancer biopsy procedures by using automated AI-driven lesion detection, classification, and 3D contouring to improve targeting precision and clinical workflow efficiency

SKU-50549